Y-mAbs Therapeutics logo

Y-mAbs TherapeuticsNASDAQ: YMAB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 September 2018

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$451.47 M
-50%vs. 3y high
64%vs. sector
-vs. 3y high
-vs. sector
-46%vs. 3y high
81%vs. sector
-75%vs. 3y high
63%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:22:51 GMT
$10.08-$1.23(-10.88%)

Dividend

No data over the past 3 years
$18.46 M$26.87 M
$18.46 M-$7.00 M

Analysts recommendations

Institutional Ownership

YMAB Latest News

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
zacks.com08 November 2024 Sentiment: NEGATIVE

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.18 per share a year ago.

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
globenewswire.com08 November 2024 Sentiment: POSITIVE

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2024.

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
globenewswire.com04 November 2024 Sentiment: POSITIVE

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, and Nobelpharma Co., Ltd. today announced that they have entered into an exclusive license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma.

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
zacks.com01 November 2024 Sentiment: NEUTRAL

YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
globenewswire.com25 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.

Y-mAbs to Participate in Upcoming Investor Conferences in October
globenewswire.com01 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) --  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that its management team will participate in the following upcoming investor conferences:

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
globenewswire.com06 September 2024 Sentiment: POSITIVE

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 – 7, 2024, at the American Academy of Cancer Research (“AACR”) Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada.

Y-mAbs to Participate in Upcoming Investor Conferences in September
globenewswire.com03 September 2024 Sentiment: POSITIVE

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the following upcoming investor conferences:

Why Y-mAbs Therapeutics Stock Got Mashed on Monday
fool.com12 August 2024 Sentiment: NEUTRAL

The commercial-stage biotech took the wraps off its second-quarter results. Revenue was up on a year-over-year basis, but it fell short of analyst estimates -- as did net loss.

Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript
seekingalpha.com12 August 2024 Sentiment: NEUTRAL

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Peter Pfreundschuh - CFO Conference Call Participants Etzer Darout - BMO Capital Markets Nicole Germino - Truist Securities Justin Walsh - JonesTrading Alec Stranahan - Bank of America Michael Ulz - Morgan Stanley John Newman - Canaccord Genuity Operator Good morning, and welcome to Y-mAbs Therapeutics Inc.'s Earnings Conference Call for the Second Quarter of 2024. At this time, all participants are in a listen-only mode.

  • 1(current)
  • 2
  • 3

What type of business is Y-mAbs Therapeutics?

Y-mAbs Therapeutics Inc is a commercial biopharmaceutical company. It is primarily engaged in the development and commercialization of new therapeutic products based on antibodies for the treatment of cancer. Its portfolio includes Naxitamab, Omburtamab, GD2-GD3 vaccine, and others. Y-mAbs Therapeutics, Inc. was founded in 2015, and its headquarters is located in New York, New York.

What sector is Y-mAbs Therapeutics in?

Y-mAbs Therapeutics is in the Healthcare sector

What industry is Y-mAbs Therapeutics in?

Y-mAbs Therapeutics is in the Biotechnology industry

What country is Y-mAbs Therapeutics from?

Y-mAbs Therapeutics is headquartered in United States

When did Y-mAbs Therapeutics go public?

Y-mAbs Therapeutics initial public offering (IPO) was on 21 September 2018

What is Y-mAbs Therapeutics website?

https://www.ymabs.com

Is Y-mAbs Therapeutics in the S&P 500?

No, Y-mAbs Therapeutics is not included in the S&P 500 index

Is Y-mAbs Therapeutics in the NASDAQ 100?

No, Y-mAbs Therapeutics is not included in the NASDAQ 100 index

Is Y-mAbs Therapeutics in the Dow Jones?

No, Y-mAbs Therapeutics is not included in the Dow Jones index

When was Y-mAbs Therapeutics the previous earnings report?

No data

When does Y-mAbs Therapeutics earnings report?

The next expected earnings date for Y-mAbs Therapeutics is 28 February 2025